{
    "id": "31be3c92-ba31-c05a-e063-6294a90a465a",
    "code": {
        "code": "34391-3",
        "codeSystem": "2.16.840.1.113883.6.1",
        "displayName": "HUMAN PRESCRIPTION DRUG LABEL"
    },
    "name": "Fludeoxyglucose F 18",
    "organization": "SOFIE Co. SOFIE",
    "effectiveTime": "20250401",
    "ingredients": [
        {
            "name": "SODIUM CITRATE, UNSPECIFIED FORM",
            "code": "1Q73Q2JULR"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "FLUDEOXYGLUCOSE F-18",
            "code": "0Z5B2CJX4D"
        }
    ],
    "indications": "1 usage fludeoxyglucose f18 injection, usp indicated positron emission tomography ( pet ) imaging following settings: fludeoxyglucose f18 injection, usp indicated positron emission tomography ( pet ) imaging following settings: oncology: assessment abnormal glucose metabolism assist evaluation malignancy patients known suspected abnormalities found testing modalities, patients existing diagnosis cancer. cardiology: identification left ventricular myocardium residual glucose metabolism reversible loss systolic function patients coronary artery disease left ventricular dysfunction, used together myocardial perfusion imaging. neurology: identification regions abnormal glucose metabolism associated foci epileptic seizures ( 1 ) . 1.1 oncology assessment abnormal glucose metabolism assist evaluation malignancy patients known suspected abnormalities found testing modalities, patients existing diagnosis cancer. 1.2 cardiology identification left ventricular myocardium residual glucose metabolism reversible loss systolic function patients coronary artery disease left ventricular dysfunction, used together myocardial perfusion imaging. 1.3 neurology identification regions abnormal glucose metabolism associated foci epileptic seizures.",
    "contraindications": "4 none. none ( 4 ) .",
    "warningsAndPrecautions": "5 radiation risks: smallest dose necessary imaging ( 5.1 ) . blood glucose abnormalities: may cause suboptimal imaging ( 5.2 ) . 5.1 radiation risks radiation-emitting products, including fludeoxyglucose f18 injection, may increase risk cancer, especially pediatric patients. smallest dose necessary imaging ensure safe handling protect patient health care worker [see . ( 2.5 ) ] 5.2 blood glucose abnormalities oncology neurology setting, suboptimal imaging may occur patients inadequately regulated blood glucose levels. patients, consider medical therapy laboratory testing assure least two days normoglycemia prior fludeoxyglucose f18 injection administration.",
    "adverseReactions": "6 hypersensitivity pruritus, edema rash reported post-marketing setting. emergency resuscitation equipment personnel immediately available. hypersensitivity occurred; emergency resuscitation equipment personnel immediately available ( 6 ) . report suspected reactions, contact sofie co. 800-207-1865 fda 1-800-fda-1088 www.fda.gov/medwatch.",
    "indications_original": "1 INDICATIONS AND USAGE Fludeoxyglucose F18 Injection, USP is indicated for positron emission tomography (PET) imaging in the following settings: Fludeoxyglucose F18 Injection, USP is indicated for positron emission tomography (PET) imaging in the following settings: Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. Neurology:  For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures ( 1 ). 1.1 Oncology For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 1.2 Cardiology For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. 1.3 Neurology For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.",
    "contraindications_original": "4 CONTRAINDICATIONS None. None ( 4 ).",
    "warningsAndPrecautions_original": "5 WARNINGS AND PRECAUTIONS Radiation risks: use smallest dose necessary for imaging ( 5.1 ). Blood glucose abnormalities: may cause suboptimal imaging ( 5.2 ). 5.1 Radiation Risks Radiation-emitting products, including Fludeoxyglucose F18 Injection, may increase the risk for cancer, especially in pediatric patients.  Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker [see Dosage and Administration . (2.5 )] 5.2 Blood Glucose Abnormalities In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels.  In these patients, consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to Fludeoxyglucose F18 Injection administration.",
    "adverseReactions_original": "6 ADVERSE REACTIONS Hypersensitivity reactions with pruritus, edema and rash have been reported in the post-marketing setting.  Have emergency resuscitation equipment and personnel immediately available. Hypersensitivity reactions have occurred; have emergency resuscitation equipment and personnel immediately available ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact SOFIE Co. at 800-207-1865 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."
}